Two studies confirm “a significant reduction in the number of infants hospitalized” thanks to this treatment, according to Public Health France.
:quality(50)/2023/07/07/64a7df4c5fe71_placeholder-36b69ec8.png)
Published
Update
Reading time: 1 min
:quality(50)/2023/09/27/maxnewsworldsix056270-65145a1687d4c566341520.jpg)
The administration of Beyfortus made it possible to avoid around 5,800 hospitalizations for bronchiolitis after going to the emergency room during the last epidemic, estimated Friday April 26 Public Health France, based on two studies carried out in collaboration with the Pasteur Institute. These studies confirm “a significant drop in the number of infants hospitalized” And “effectiveness of the treatment” for infants admitted to intensive care, underlines the health authority in a press release.
A preventive immunization campaign against bronchiolitis was launched on September 15 by the government via the administration of nirsevimab (Beyfortus®) “to protect infants and slow the circulation of this virus”. Nearly 250,000 doses have been administered in France. In order to evaluate the effectiveness of this treatment, two studies were carried out by Public Health France and the Pasteur Institute. The first to estimate the effectiveness on patients admitted to intensive care. The other to assess the impact in terms of avoided hospitalizations.
“A reduction of 23% in the total number of hospitalizations”, after going to the emergency room
The results of the first study, carried out in mainland France from September 15, 2023 to January 31, 2024 with 288 infants, “confirm the real-life effectiveness of nirsevimab in preventing serious cases of RSV bronchiolitis hospitalized in intensive care”. This efficiency is “estimated between 76% and 81% for infants admitted to intensive care”. These analyzes “consistent with the results of an international clinical study carried out on 8,058 infants”specifies Public Health France.
According to the modeling work of the second study, the administration of the treatment also “made it possible to avoid around 5,800 hospitalizations for RSV bronchiolitis after going to the emergency room, including 4,200 in children aged 0 to 2 months, between September 15, 2023 and February 4, 2024, in mainland France”, adds the health authority. This corresponds to “a 23% reduction in the total number of hospitalizations” after going to the emergency room. Finally, researchers estimate that hospitalization for bronchiolitis was avoided for around 40 children treated against this virus.
